May 14, 2018 Bio/Pharma/CRO Mass Spectrometry Product Launch

SCIEX Announces New BioPharmaView Software 3.0 for Streamlining Multiple-Attribute Methods (MAM)

Complete and easy-to-use LC-MS-based solution for biotherapeutics characterization and quality testing May 14, 2018 Framingham, MA — SCIEX, a global leader in life science analytical technologies, today announced the newly released BioPharmaView™ Software 3.0 solution for the complete LC-MS Multiple Attribute Methodology (MAM) Workflow, that enables simple yet in-depth characterization of biologics through powerful mass spectrometry.... Read more

May 14, 2018 Bio/Pharma/CRO PR/Corporate Product Launch

Roche to present new phase III data for Hemlibra in people with haemophilia A at the World Federation of Hemophilia 2018 World Congress

Basel, 14 May 2018 Roche to present new phase III data for Hemlibra in people with haemophilia A at the World Federation of Hemophilia 2018 World Congress Data include results from HAVEN 3 study in people with haemophilia A without factor VIII inhibitors and HAVEN 4 study in people with haemophilia A with or without... Read more

May 14, 2018 Bio/Pharma/CRO PR/Corporate Product Launch

Roche to present new phase III data for Hemlibra in people with haemophilia A at the World Federation of Hemophilia 2018 World Congress

Basel, 14 May 2018 Roche to present new phase III data for Hemlibra in people with haemophilia A at the World Federation of Hemophilia 2018 World Congress Data include results from HAVEN 3 study in people with haemophilia A without factor VIII inhibitors and HAVEN 4 study in people with haemophilia A with or without... Read more

May 10, 2018 Bio/Pharma/CRO

Roche provides update on Phase III study of Tecentriq (atezolizumab) and Cotellic (cobimetinib) in people with heavily pre-treated locally advanced or metastatic colorectal cancer

Basel, 10 May 2018 Roche provides update on Phase III study of Tecentriq (atezolizumab) and Cotellic (cobimetinib) in people with heavily pre-treated locally advanced or metastatic colorectal cancer Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the Phase III IMblaze370 study evaluating the combination of Tecentriq® (atezolizumab) and Cotellic® (cobimetinib) did not meet its... Read more

May 10, 2018 Bio/Pharma/CRO

Roche provides update on Phase III study of Tecentriq (atezolizumab) and Cotellic (cobimetinib) in people with heavily pre-treated locally advanced or metastatic colorectal cancer

Basel, 10 May 2018 Roche provides update on Phase III study of Tecentriq (atezolizumab) and Cotellic (cobimetinib) in people with heavily pre-treated locally advanced or metastatic colorectal cancer Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the Phase III IMblaze370 study evaluating the combination of Tecentriq® (atezolizumab) and Cotellic® (cobimetinib) did not meet its... Read more

April 30, 2018 Bio/Pharma/CRO Molecular Spectroscopy Product Launch

RedShiftBio Launches New Protein Characterization Instrument System – AQS3pro

See Change™ with the new AQS3pro System for protein characterization from RedShiftBio. One highly automated system, five key measurements: Aggregation, Quantification, Stability, Structure and Similarity April 30, 2018 07:59 AM Pacific Daylight Time BOSTON–(BUSINESS WIRE)–At PEGS 2018 (April 30th – May 4th, Boston, MA) RedShift™ BioAnalytics, Inc. (RedShiftBio™) will unveil the AQS3™pro, a new protein... Read more

April 30, 2018 Atomic Spectroscopy Bio/Pharma/CRO Molecular Spectroscopy Product Launch

Unchained Labs brings in the muscle with Bouncer and releases the Hounds!

April 30, 2018 – Pleasanton, CA – Unchained Labs, the life sciences company that’s all about getting biologics researchers the right tool for the job, launched Hound and Bouncer today at the PEGS conference in Boston. The QC duo are the ultimate tools for getting biopharmaceutical manufacturers to particle-free biologics and trouble-free drug delivery devices... Read more